Anders Osterborg
Overview
Explore the profile of Anders Osterborg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
169
Citations
5010
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sadeghi L, Merrien M, Bjorkholm M, Osterborg A, Sander B, Claesson H, et al.
Int J Mol Sci
. 2025 Mar;
26(5).
PMID: 40076826
Chronic lymphocytic leukemia (CLL) cells depend on microenvironment niches for proliferation and survival. The adhesion of tumor cells to stromal cells in such niches triggers the activation of signaling pathways...
2.
Hedberg P, Blixt L, Eketorp Sylvan S, Killander Moller I, Lindahl H, Kahn F, et al.
Blood Adv
. 2025 Feb;
PMID: 39983071
Individuals with chronic lymphocytic leukemia (CLL) face increased risk of severe COVID-19. This study from Sweden, a country with few mandatory restrictions at the onset of the pandemic, used 10...
3.
Shadman M, Munir T, Robak T, Brown J, Kahl B, Ghia P, et al.
J Clin Oncol
. 2024 Dec;
43(7):780-787.
PMID: 39647999
JCO SEQUOIA (ClinicalTrials.gov identifier: NCT03336333) is a phase III, randomized, open-label trial that compared the oral Bruton tyrosine kinase inhibitor zanubrutinib to bendamustine plus rituximab (BR) in treatment-naïve patients with...
4.
Zhong W, Kokhaei P, Mulder T, Ghaderi A, Moshfegh A, Lundin J, et al.
Cancers (Basel)
. 2024 Nov;
16(22).
PMID: 39594776
Background/objectives: Nurse-like cells (NLCs) derived from monocytes in the tumor microenvironment support the growth of chronic lymphocytic leukemia (CLL) cells. Here, we investigated the effects of a CX3CR1 (fractalkine receptor)...
5.
Lindahl H, Kahn F, Nilsdotter-Augustinsson A, Fredrikson M, Hedberg P, Killander Moller I, et al.
J Allergy Clin Immunol
. 2024 Oct;
155(2):387-397.e6.
PMID: 39447887
Background: It is thought that patients with inborn errors of immunity (IEI) are more susceptible to severe coronavirus disease 2019 (COVID-19) than the general population, but a quantification of this...
6.
Chen P, Bergman P, Blennow O, Hansson L, Mielke S, Nowak P, et al.
EBioMedicine
. 2024 Oct;
109:105385.
PMID: 39395230
Background: Immunocompromised patients with primary and secondary immunodeficiencies have shown impaired responses to SARS-CoV-2 mRNA vaccines, necessitating recommendations for additional booster doses. However, longitudinal data reflecting the real-world impact of...
7.
Killander Moller I, Hedberg P, Wagner P, Lindahl H, Nystrom S, Blixt L, et al.
Infect Dis (Lond)
. 2024 Sep;
57(2):178-191.
PMID: 39320271
Background: Data on the outcomes of COVID-19 in people living with HIV (PLHIV), specifically in relation to vaccination status, are lacking during the Omicron era. Methods: This nationwide registry-based study...
8.
Brown J, Eichhorst B, Lamanna N, OBrien S, Tam C, Qiu L, et al.
Blood
. 2024 Sep;
144(26):2706-2717.
PMID: 39316666
The ALPINE trial established the superiority of zanubrutinib over ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma; here, we present data from the final comparative analysis...
9.
Kater A, Owen C, Moreno C, Follows G, Munir T, Levin M, et al.
NEJM Evid
. 2024 Feb;
1(7):EVIDoa2200006.
PMID: 38319255
BACKGROUND: GLOW is a phase 3 trial evaluating the efficacy and safety of ibrutinib-venetoclax in older patients and/or those with comorbidities with previously untreated chronic lymphocytic leukemia (CLL). METHODS: We...
10.
Muller T, Gao Y, Wu J, Ribeiro O, Chen P, Bergman P, et al.
Cell Host Microbe
. 2024 Jan;
32(2):156-161.e3.
PMID: 38211584
T cells are critical in mediating the early control of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) breakthrough infection. However, it remains unknown whether memory T cells can effectively cross-recognize...